Overview
This study plans to learn how endothelial cells, single cell lining of blood vessels may be dysfunctional after a spinal cord injury. Endothelial dysfunction will be measured by the capacity of blood vessels to vasodilate (increase in size) and alter blood flow is lower in adults with a spinal cord injury in comparison to adults without a spinal cord injury. The mechanisms which may alter this function may be critical in reducing the risk of heart attacks and strokes in people with spinal cord injuries.
Description
Vascular endothelial dysfunction is prevalent after spinal cord injury (SCI) which predispose individuals with SCI to accelerated, atherosclerotic cardiovascular disease (ASCVD) and future myocardial infarctions and ischemic strokes. The central objective of this study is to determine whether adults with SCI exhibit impaired endothelial function. Specifically, if endothelium-dependent vasodilation is impaired and if endothelial cell derived microvesicles (EMVs) are elevated and dysfunctional in adults with paraplegia. Endothelium-dependent vasodilation will be assessed by pharmacologically manipulating endothelial vasodilator function in live conscious humans with SCI and determining the role of circulating EMVs as both a systemic biomarker and mediator of endothelial dysfunction.
Eligibility
SCI Inclusion Criteria
- Over age 18 years
- Chronic (\>12 months) SCI
- Motor complete (AIS A/B) SCI
- Paraplegia (neurological level of injury \[NLI\] at T2 or below)
Non-injured Inclusion Criteria
• Over age 18 years
Exclusion Criteria (Both SCI and Non-injured)
- Overt chronic diseases as assessed by: a) clinically documented medical history; b) physical examination; c) blood pressure and ECG at rest; and d) complete blood chemistries and hematological evaluation.
- Active infection
- Recent (\< 3 months) surgery
- Current smoking history (within past 12 months)
- Report more than low-risk alcohol consumption
- History of drug abuse
- Currently taking cardiovascular (statins, beta-blockers) therapeutics and/or other medications that could influence the outcome measures